Kailera Therapeutics files for proposed Nasdaq IPO

Kailera Therapeutics has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate that we believe offers the potential for the greatest weight loss."

J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI will serve as lead underwriters.

You May Also Be Interested In

• Vogenx prices IPO at $13 per share, raising $81.3M
• Alabama Power Co. 5.875% Sr. Notes Series 2007b (ALM) Tops Q2 EPS by 62c
• Hour Loop, Inc. (HOUR) Reports Q2 EPS of $0.03